TORVANTA
Other · S&P 500 · data as of 2026-10-05

INVA stock analysis: INVA

INVA (INVA) is an S&P 500 company in Other. It grades strongest on value and profitability.

The model's view of INVA · subscribers

Where INVA ranks among the 1,500 U.S. stocks the model scores each trading day, its expected return, the evidence for and against it, and whether the model portfolio holds it. The grades below describe the company's data; they are not the model's view.

See plans
What's happening with INVA · updated 2026-10-05 · from prices and SEC filings

INVA price performance

INVA against the S&P 500, one year
+0%+20%S&P 500 +18%INVA +8%2025-09-292026-10-05
Year to date+3.2%S&P 500 +14.5% · behind by 11.3 pts
1 year+18.1%S&P 500 +17.0% · ahead by 1.0 pts
3 years+56.0%S&P 500 +89.3% · behind by 33.2 pts
5 years+24.7%S&P 500 +91.3% · behind by 66.6 pts

Total returns with dividends reinvested.

INVA factor grades

Each grade compares INVA with the rest of its sector (A+ best, F worst); the numbers behind it are shown with the typical figure for its peers.

AValueP/E 5.0x (industry 20.1x)FCF yield 12.7% (industry 6.0%)
B+GrowthRevenue growth +19% (industry +8%)EPS growth +1042% (industry +10%)
A-ProfitabilityOperating margin 36.9% (industry 9.6%)ROIC 15.0% (industry 10.1%)
C+Momentum12-month change +18%From 52-wk high -15%

INVA in plain numbers

INVA key statistics

SectorOther
Industryn/a
IndexS&P 500
Market value$1.5B
Revenue growth (y/y)+19%
Free-cash-flow yield12.7%
Dividend yieldn/a
Next earnings (expected)2026-11-04
Valuation measures
Market value$1.5B
Enterprise value$1.2B
P/E (trailing)5.0x
Forward P/E (Torvanta estimate)3.3x
PEG (Torvanta estimate)0.07
Price / sales3.4x
Price / book1.2x
EV / revenue2.7x
EV / EBITDA7.3x
Financial highlights
Revenue, last 12 months$440.0M
Net income, last 12 months$357.2M
EPS, last 12 months (GAAP)$4.11
Gross margin72.2%
Operating margin36.9%
Net margin81.2%
Return on equity36.7%
Return on invested capital15.0%
Cash$570.4M
Total debt$258.5M
Debt / equity0.21x
Free cash flow, last 12 months$189.4M
Interest cover8.9x
Current ratio16.01x

Company figures from its latest SEC filings; market value and returns from end-of-day prices.

INVA earnings trends

Revenue vs earnings
-$83.4M-$15.9M$51.6M$119.1M$186.6MSep 2024 Revenue: $89.5MDec 2024 Revenue: $91.8MMar 2025 Revenue: $88.6MJun 2025 Revenue: $100.3MSep 2025 Revenue: $107.8MDec 2025 Revenue: $114.6MMar 2026 Revenue: $98.0MJun 2026 Revenue: $119.6MSep 2024 Net income: $1.2MDec 2024 Net income: $20.3MMar 2025 Net income: -$46.6MJun 2025 Net income: $63.7MSep 2025 Net income: $89.9MDec 2025 Net income: $164.2MMar 2026 Net income: $186.6MJun 2026 Net income: -$83.4MSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Net margin: 1.4%Net margin: 22.1%Net margin: -52.6%Net margin: 63.5%Net margin: 83.4%Net margin: 143.2%Net margin: 190.4%Net margin: -69.8%-70%60%190%■ Revenue ■ Net income ━ Net margin
Earnings per share$-1.1$-0.3$0.5$1.4$2.2Sep 2024 EPS (GAAP, diluted): $0.0Dec 2024 EPS (GAAP, diluted): $0.3Mar 2025 EPS (GAAP, diluted): $-0.7Jun 2025 EPS (GAAP, diluted): $0.8Sep 2025 EPS (GAAP, diluted): $1.1Dec 2025 EPS (GAAP, diluted): $2.0Mar 2026 EPS (GAAP, diluted): $2.2Jun 2026 EPS (GAAP, diluted): $-1.1Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026■ EPS (GAAP, diluted) Change from a year earlier: Sep 2025 +5300% · Dec 2025 +529% · Jun 2026 -248%

From the company's 10-Q and 10-K filings with the SEC.

INVA financials (from SEC filings)

Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue$391.9M$331.3M$310.5M$358.7M$411.3M
Net income$368.8M$220.3M$179.7M$23.4M$271.2M
EPS (GAAP)$2.88$2.35$2.17$0.24$3.06
Free cash flow$363.8M$201.7M$140.7M$188.4M$195.8M

INVA earnings history

ReportedEPS (GAAP)EPS y/yRevenue y/yStock vs S&P 500, 2 days
2026-08-05$-1.14-248%+19%+1.6%
2026-05-06$2.22n/a+11%-0.4%
2026-02-25$1.95+529%+25%+0.2%
2025-11-05$1.08+5300%+20%+14.1%
2025-08-06$0.77n/a+0%-0.6%
2025-05-07$-0.74-261%+14%-1.8%

About INVA

HeadquartersBurlingame, CA
Industry (SEC code)Pharmaceutical Preparations
Fiscal year endsDecember 31
Incorporated inDE
Listed onNasdaq
FormerlyTHERAVANCE INC, ADVANCED MEDICINE INC

From the company's SEC registration record.

Companies similar to INVA

CompanyMarket valueP/ERevenue growthOperating margin12-month change
INVA INVA$1.5B5.0x+19%36.9%+18%
EFC EFC$1.5B7.1xn/an/a-3%compare
EFOR EFOR$1.5B18.6x-1%4.9%-26%compare
SBH SBH$1.5B8.4x+1%8.4%-3%compare
TFIN TFIN$1.5B41.6xn/an/a+26%
CRSR CRSR$1.5B43.6x+3%2.9%+68%
KMPR KMPR$1.5Bn/a-4%n/a-47%

All Other stock ratings

Frequently asked questions

Is INVA stock a buy?

Torvanta does not tell individuals what to buy. Its grades for INVA are shown above. Subscribers see the model's rank, expected return and whether the model portfolio holds it. This is research, not a recommendation.

What is INVA's P/E ratio?

INVA trades at about 5.0 times its last 12 months of GAAP earnings reported to the SEC, and about 3.3 times Torvanta's own estimate of the next 12 months.

When does INVA report earnings next?

Based on its filing history, Torvanta expects INVA to report around 2026-11-04.

How has INVA performed against the S&P 500?

Over the past year INVA returned +18.1%, against +17.0% for the S&P 500, dividends reinvested.

See the model's view

Subscribers get the model's rank and expected return for every covered company, the reasoning behind each, and the Torvanta model portfolio's trades each trading day, sized and explained, at three risk levels.

See plans Or get the free weekly newsletter

Torvanta is research only - not investment advice and not a recommendation to buy or sell any security. Grades describe a company's reported data against its sector; they are not the model's view, change as data changes and can be wrong. Financial figures come from the company's SEC filings; returns include reinvested dividends. Past performance does not predict future results.

All stock ratings · Stock lists · AI stock research · Model portfolio · Research · Disclaimer